ARGININE VASOPRESSIN (AVP) is a neuropeptide that exerts significant effects on circulatory and water homeostasis. AVP acts on three G protein-coupled receptors (GPCR), namely V1a, V1b, and V2 (1) . V1a affects smooth and myocardial muscle contractility, V1b acts on the pituitary to elicit adrenocorticotropic hormone release, while vasopressin type 2 receptor (V2R) is mostly expressed in epithelium of the renal collecting tubule where it mediates the hydroosmotic effects of vasopressin (30, 56) . V2R is also present on vascular endothelium to elicit vasorelaxation (6, 49, 50, 57, 58) . Several clinical conditions have been associated with inappropriately elevated levels of AVP including heart failure, cirrhosis of the liver, and the syndrome of inappropriate secretion of antidiuretic hormone; a role for vasopressin in shock has also been documented (70) . Under these conditions, V2R plays a dominant role in retaining water and in inhibiting myocardial contractility (69, 74) . Congruently, mutations in the V2R gene have been associated with X-linked recessive nephrogenic diabetes insipidus disorder (loss of function) (9, 73) and with the nephrogenic syndrome of inappropriate antidiuresis (gain of function) (20) . Accordingly, a number of AVP antagonists have been proposed for clinical applications. In this context, V2R antagonists exhibit notable efficacy as aquaretics for heart failure and hepatorenal syndrome with inappropriate secretion of AVP, possibly in patients with polycystic kidneys, and may improve myocardial contractility during shock secondary to burns (70) ; conversely V2R agonists are useful for diabetes insipidus (1, 63, 64) . Most of these drugs are analogs of AVP (1) and hence exhibit competitive antagonist or agonist properties by interacting with the orthosteric binding site of the ligand; some of these compounds identified by random screening (76) partially bind to the orthosteric site (47) . In contrast, efficacy of complete noncompetitive antagonists would either 1) be unaffected by orthosteric agonist concentrations if cooperativity is neutral between the two agents, or 2) the antagonism accrued if there is negative cooperativity of the drug on the orthosteric agonist. These properties may result in functional selectivity (72) , but such compounds have yet to be developed for V2R.
The concept that peptides, which reproduce the sequence of specific regions of proteins, can interfere with their actions has been adequately documented (12, 52, 66) . In this context, the extracellular loops of GPCRs (including vasopressin receptors) exhibit important roles on ligand affinity and hence on receptor conformation (11, 29, 36, 67) . There is increasing evidence that peptides arising from various juxtamembranous and extracellular regions of GPCRs remote from the natural ligand binding site can interfere with their respective actions as documented, for instance, for PGF 2␣ receptor (59) , CCR5 (35) , ␤ 2 -adrenoceptors (28) , and protease-activated receptor 1 (23, 41) ; consequently, these compounds exert noncompetitive properties. Also, diverse ligands that can act on the same receptor have the potential of affecting certain but not all signaling pathways; thus one ligand can preferentially activate one pathway, while another can preferentially activate a second pathway. The latter concept, termed functional permissiveness, confers greater selectivity and has been described for numerous compounds (21, 31, 72) , including noncompetitive antagonists (32, 43) .
On the basis of the overall rationale presented above, we generated peptides derived from extracellular juxtamembranous regions of V2R and screened them against V2R agonistinduced effects. Compounds were tested on a (complex) multisignal-dependent physiological function, notably vasomotricity to identify relevant effective molecules, rather than separate signaling markers, which may not detect compounds exhibiting significant functional selectivity (21, 31, 72) . We hereby describe for the first time a selective noncompetitive (peptide) antagonist of V2R, VRQ397, which exhibits functional selectivity, and in vivo, is an effective aquaretic.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (250 -300 g body wt) and nonpregnant female CD1 mice (Charles Rivers, St. Constant, Quebec) were used according to a protocol approved by the Ste-Justine Hospital Animal Care Committee as well as along the principles of the Guide for the Care and Use of Experimental Animals of the Canadian Council on Animal Care. Animals were anesthetized with isofluorane (2.5%, vol/vol), and the cremasteric muscle or uterus were, respectively, excised and placed in an ice-cold Krebs buffer (pH 7.4) of the following composition (in mM): 120 NaCl, 4.4 KCl, 2.5 CaCl 2, 1.0 MgCl 2, 27 NaHCO3, 1.0 KH2PO4, and 10 glucose. All chemicals were purchased at Sigma-Aldrich (Oakville, ON, Canada).
Peptide synthesis. Peptides [CRAVKY (labeled VRQ397) and analogs] were synthesized on an ACT-348-Omega peptide synthesizer at 25-mol scale using a fivefold excess of Fmoc-L-amino acids (125 mM) relative to the Fmoc-L-AA-Wang resin (commercial loadings between 0.4 and 0.9 mmol/g; 0.9 mmol/g for Fmoc-Tyr-Wang Resin). Fmoc protecting group removal was performed using 20% piperidine in dimethylformamide (DMF). Double coupling was performed using 1:1:1 amino acid/1,3-diisopropylcarbodiimide/1-hydroxybenzotriazole hydrate. In between the deprotection and coupling steps the resin was washed successively with DMF, MeOH, and DMF. Final peptide cleavage was performed with 81.5:5:5:5:2.5:1 trifluoroacetic acid (TFA)/ thioanisole/phenol/water/1,2-ethanedithiol/triisopropylsilane, and the solution was freeze dried. Typically 5-7 mg of the crude peptide were taken in 0.5-0.7 ml of a 9:1 mixture of water/DMSO and agitated for 30 s on a benchtop centrifuge. The contents were filtered through a 0.2-m syringe filter. The resulting filtrate was lyophilized to a dry powder (2-5 mg), which was further analyzed by HPLC followed by mass spectrometry analysis. Crude peptides were analyzed on a Varian ProStar HPLC on a Phenomenex Jupiter 5u C-18, 300A column, 150 ϫ 4.6 mm. The gradient was 0 -100%B over 20 min. Solvent A was 10% aqueous acetonitrile with 0.1% TFA, and solvent B was 70% acetonitrile/30% water with 0.1% TFA. The flow rate was 1 ml/min, and the detection was at 220 nm. Peptides were in this way esteemed to be Ͼ 95% pure prior to biological examinations.
Cell culture. Native HEK293 cells and HEK293 cells stably expressing the human V2 receptor were cultured in DMEM high glucose (10% FBS, 1% pencillin/streptomycin; GIBCO Invitrogen, Burlington, ON, Canada) (55); stably transfected cells were grown in the presence of G418 (200 g/ml; Promega, Madison WI).
Vasomotor response. Microvessels from the rat cremasteric muscles were visualized ex vivo and recorded with a video camera (model CCD72; Dage-MTI, Michigan City, MI) mounted on a dissecting microscope (model M-400; Nikon), as amply reported (26, 44) . To determine the vasomotor response, vascular diameter was measured with a digital image analyzer (Sigma Scan software; Jandel Scientific, Corte Madera, CA); measurements were repeated four times and presented a variability of Ͻ2%.
Briefly, cremasteric muscles were pinned securely to a wax base of a 20-ml bath containing Krebs buffer saturated with 95% O2-5% CO2 and maintained at 37°C. The tissue was allowed to equilibrate for 45 min before vasomotor responses of third-order arterioles (30 -70 m) were recorded. Vascular diameter was recorded before and after topical application of the agents described below.
Responses to the vasorelaxant desmopressin-L-desamino-8-arginine-vasopressin (DDAVP; Sigma-Aldrich) were determined on tissues preconstricted with either KCl (20 mM) or the thromboxane A 2 mimetic U46619 (0.1 M; Cayman Chemical/Cedarlane, Hornby, ON, Canada) for 30 min; because effects of KCl and U46619 were analogous, experiments were pursued mostly with U46619. Cremasteric muscle was preincubated or not for 30 min with drugs of interest, specifically 1) the V1a receptor antagonist SR49059 (68); 2) the V2 receptor antagonist SR121463A (42) (both compounds were generous gifts of C. Serradeil-LeGal, Sanofi Research, Toulouse, France); 3) peptides described in RESULTS; 4) 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ; 100 M; Sigma-Aldrich) (7); 5) ibuprofen (10 M; Sigma-Aldrich) (45); or 6) respective vehicle (ineffective). Response to DDAVP was subsequently determined. DDAVP alone had 10 nM EC 50. Vasorelaxation to substance P (Sigma-Aldrich), bradykinin (Sigma-Aldrich), and carbacyclin (Cayman Chemical/ Cedarlane) was tested in a similar manner. Some experiments were also conducted after endothelial denudation. Endothelial denudation was performed as previously described using intravenous administration of 3-[(3-cholamidopropyl)-dimethylammoniol]-2-hydroxy-1-propylsulfonate (CHAPS; 5 mg/l for 10 min) (38) . As expected, CHAPS abolished endothelium-dependent relaxation to acetylcholine, but did not affect relaxation to carbacyclin (1 M) or constriction to U46619 (0.1 M). We also tested constriction of cremasteric vessels to AVP in the presence or absence of VRQ397. Vasorelaxation was expressed as the percentage of reversal of KCl or U46619-induced constriction, while vasoconstriction was expressed as the percentage of the constriction to AVP.
Isometric contraction of myometrial preparations. Uterine strips (2-to 3-mm wide and 1-to 2-cm long) from CD1 mice were suspended in organ baths containing Krebs buffer treated with bubbles of 21% O2-5% CO2 at 37°C and equilibrated for at least 1 h, as previously described (59) . Initial tension was set at 2 g. After a 1-h period of equilibration, the uterine strips were pretreated with the vehicle VRQ397 or atosiban (Sigma-Aldrich) and thereafter stimulated with oxytocin (American Peptide, Sunnyvale, CA). Changes in mean basal tension as well as frequency of contractions were recorded using a Kent digital polygraph system.
Binding assays. Peptide iodination was performed using the chloramine T method labeling of peptides and proteins by radioiodination (4) . Binding assay with [
125 I]VRQ397 (2,200 Ci/mmol) was performed on whole cells as described (44, 48, 62) . Essentially, HEK293 cells stably expressing V2R and native cells were plated in 24-well dishes pretreated with poly-D-lysine (Sigma) for 12 h prior to the experiment; cells were 90% confluent on the experimental day. Cells were then placed on ice, washed twice with 1 ml of binding buffer (PBS/0.05% BSA) and treated with [
125 I]VRQ397 (10 nM) in binding buffer in the presence or absence of noniodinated VRQ397 (1 M) for 2 h. Unbound ligand was washed away with ice-cold binding buffer (3ϫ 1 ml), and the remaining cell-bound ligand concentration was determined using a gamma counter after cell lysis at room temperature (0. ]oxytocin was ϳ10 -12%. After filtration through GF/C filters, the radioactivity on cell mem-brane was determined. The specific binding was calculated for each condition and expressed as a percent of the specific binding determined in the absence of unlabeled compound. Hill coefficient of saturation isotherm was calculated using the software GraphPad Prism to determine whether the binding followed a law of mass action or cooperativity. Saturation curves of Measurements of 6-keto-PGF 1␣ and cAMP. The levels of 6-keto-PGF1␣ (stable metabolite of PGI2; Cayman Chemical/Cederlane) were measured in cremasteric tissue by radioimmunoassay as previously detailed (44) . The production of cAMP in HEK293 cells was also measured by radioimmunoassay as per instructions of the manufacturer (GE Healthcare). Briefly, cells were stimulated with DDAVP (different concentrations) for 15 min in the presence or absence of VRQ397 or SR121469 (100 nM). Culture media was removed and 1-propanol added to extract cAMP from cells for 1 h at 4°C. Extracts were dried and reconstituted in assay buffer, and protein concentration was determined on the cells using the Bradford technique; cAMP was determined by radioimmunoassay.
Bioluminescence resonance energy transfer assay. Stable HEK293 cell lines coexpressing V2R-VENUS and ␤-arrestin2-Renilla luciferase (Rluc) were employed for monitoring V2R signaling by bioluminescence resonance energy transfer (BRET) as we described (25) . A monolayer of cells was washed once with PBS and then gently detached by pipetting in PBS supplemented with 0.1% D-glucose. Approximately 30,000 cells were dispensed into 96-well white opaque plates (Corning). To measure the BRET signal the BRET1 substrate for Rluc, coelenterazine-h (Prolume, Pinetop, AZ) was added to a final concentration of 5 M, and the BRET1 was measured on the FUSION (Perkin Elmer) plate reader, which allowed the sequential integration of signals detected in 470 Ϯ 30 nm and 550 Ϯ 40 nm windows. The BRET signal was calculated as a ratio of the light emitted by VENUS (550 Ϯ 40 nm) over the light emitted by Rluc (470 Ϯ 30 nm). DDAVP-induced BRET was calculated by subtracting the BRET ratio obtained in the absence of the agonist from the one obtained in the presence of an agonist with or without antagonist.
Measurement of diuresis. Rats were anesthetised with isoflurane (2.5% vol/vol) and the jugular vein was cannulated with polypropylene catheter (PE-90) for infusion of saline (150 ml ⅐ kg Ϫ1 ⅐ day Ϫ1 ; Harvard pump) with or without VRQ397 (begun 2 h after baseline urine output determined); carotid artery was also catheterized to collect blood for creatinine and osmolality measurements at baseline and hourly for 3 h (after VRQ397 adiminstration). A midline abdominal incision was also made to reveal the bladder from which urine was collected via an inserted cannula. The bladder was emptied and strict 60-min urine collected for volume, creatinine, and osmolality measurements; a 2-h baseline was established after which VRQ397 was infused. Creatinine clearance was calculated as: (U creat ϫ urine volume)/Pcreat, where Ucreat and Pcreat refer to urinary and plasma 
RESULTS

Screening of peptides derived from extracellular juxtamembranous regions.
Six L-peptides, which reproduce extracellular juxtamembranous regions of V2R were designed (Fig. 1) . We intentionally avoided the seventh juxtamembranous region of V2R wherein the transmembrane domain is important for AVP binding (15, 61) , as we aimed to generate noncompetitive antagonists. Regions of the receptor chosen exhibited homology for human, rat, and mouse. Compounds were screened against DDAVP-induced cremasteric vasorelaxation of previously U46619-generated vasoconstriction. DDAVP-induced cremasteric vasorelaxation was confirmed as V2R-dependent, as established V2R-selective competitive antagonist SR121463 (42, 68) abolished the vasorelaxation (Fig. 2A) ; the V1aR selective antagonist SR49059 was ineffective ( Fig. 2A) . VRQ181, VRQ184, and more profoundly, VRQ183 (1 M; ALCRAVKY) inhibited DDAVP-induced vasorelaxation; elimination of the cysteine residue, substituted with serine (ALSRAVKY), abrogated efficacy of the compound (Fig. 2B) . Because of the reproducibility of ALCRAVKY's high efficacy, experiments were pursued with this peptide. In the course of determining sufficient sequence required for activity, amino acid deletions of the tyrosine with or without lysine virtually abolished inhibitory efficacy (Ͻ10%). Whereas sequential deletion of the alanine and leucine yielded, respectively, fully effective LCRAVKY (IC 50 ϭ 58 Ϯ 22 nM) and the more potent hexapeptide CRAVKY (termed VRQ397; IC 50 ϭ 0.69 Ϯ 0.25 nM) (Fig. 2B) , VRQ397 was as effective and potent as SR121463 (IC 50 ϭ 0.65 Ϯ 0.2 nM; Fig. 2A ).
Selectivity and noncompetitive properties of VRQ397. We next determined the selectivity of VRQ397 for V2R. [ 125 I]VRQ397 saturably bound to HEK293 cells expressing V2R (Fig. 3A) (Fig. 3C ). In line with these observations [ 125 I]VRQ397 hardly bound to HEK293 cells expressing V1a or oxytocin receptor ( Fig. 3C and Supplementary Fig. 1 posted online with this article); the latter was tested because vasopressin and oxytocin receptors are closely related (22) , including in the corresponding region from which cravky arises (oxytocin receptor sequence: crlvky). Findings suggested that VRQ397 bound to V2R.
The selectivity of VRQ397 for V2R-induced effects was further studied on V1a and oxytocin receptor-evoked effects. Cremasteric vasoconstriction to AVP was unaffected by VRQ397, as this is a V1a-dependent process fully inhibitable by the V1a antagonist SR49059 (Fig. 4A) . VRQ397 (up to 10 M) was also ineffective in preventing oxytocin-induced myometrial (abundant in oxytocin receptor) contraction, whereas the oxytocin antagonist atosiban (10 M) (54) fully prevented it (Fig. 4B) . Consistent with these observations, along the same lines of reasoning, since cremasteric vasorelaxant effects of DDAVP are endothelium-dependent (see below), we tested whether VRQ397 interfered with effects of distinct endotheliumdependent mediators, notably bradykinin and substance P. Bradykinin-and substance P-induced vasorelaxation was unaltered by VRQ397 (Fig. 4, C and D) . In addition, effects of (endotheliumindependent) carbacyclin were also unaffected by VRQ397 (Fig. 4E) . We then tested whether VRQ397 bound to the same V2R site as DDAVP. VRQ397, but not DDAVP, dose-dependently fully displaced bound [ 125 I]VRQ397 in V2R-expressing HEK293 cells (Fig. 5A) , and likewise DDAVP but not VRQ397 dose-dependently displaced bound [ 3 H]AVP (Fig. 5B ). These observations were corroborated by determining whether VRQ397 inhibited DDAVP-induced vasorelaxation in a competitive or noncompetitive manner. Vasorelaxation was studied in tissues pretreated with different concentrations of VRQ397 in the presence of increasing concentrations of DDAVP. VRQ397 dimin- ished concentration-dependent maximum vasorelaxation induced by DDAVP (Fig. 5C and Supplementary Table 1 , posted with the online version of this article). We further investigated whether VRQ397 affected AVP dissociation rate (k OFF ). In the absence of VRQ397 dissociation half-life (t 1/2 ) of AVP was 10.07 Ϯ 2.2 min with a k OFF of 0.069 Ϯ 0.01 min, while in the presence of VRQ397 the dissociation t 1/2 was more rapid and the k OFF accordingly greater, respectively, 3.6 Ϯ 0.55 min and 0.193 Ϯ 0.057 min (Fig. 5D) . Collectively, these findings infer that VRQ397 specifically binds to V2R at a site distinct from that of the orthosteric ligand (AVP/ DDAVP) binding site as a noncompetitive antagonist, but modulates AVP binding (13) .
Mechanism of VRQ397 antagonism of DDAVP-induced vasorelaxation. Vasorelaxation to V2R stimulation is foremost considered to be secondary to induction of endothelium-derived relaxant prostaglandin generation, notably prostacyclin (8, 27, 49, 50, 53) . Accordingly, endothelial denudation, acetylcholine-and substance P-insensitive vasorelaxation, using CHAPS and the cyclooxygenase inhibitor ibuprofen, abolished DDAVP-induced relaxation (Fig. 6A) ; contraction to U46619 and relaxation to carbacyclin were not affected by CHAPS, indicating integrity of smooth muscle (Fig. 6A) . ODQ, the inhibitor of the major NO target, guanylate cyclase, was ineffective. Consistent with these observations, DDAVP increased formation of PGI 2 (measured through its stable metabolite 6-keto-PGF 1␣ ) in cremasteric muscle, was, as expected, prevented by ibuprofen and SR121463, as well as by VRQ397 (Fig. 6B) .
V2R classically associates with G s to elicit cAMP formation (5); the same applies with the PGI 2 receptor, classified as IP (75) . Attempt to measure cAMP generation in response to DDAVP stimulation of cremasteric tissue was unsuccessful, possibly because the marginal increase generated by the microvasculature of this ubiquitously abundant cyclic nucleotide could not be detected. On the other hand, stimulation of V2R-expressing HEK293 cells induced a concentration-dependent increase in cAMP formation, which was unaltered by VRQ397 (Fig. 6, C and D) but largely inhibited by the V2R orthosteric antagonist SR121463 (Fig. 6C) (68) . Likewise, another coupling event of V2R, specifically ␤-arrestin2 recruitment (detected by BRET assay) (13) measured on V2R-expressing HEK293 cells was, as expected, prevented by SR121463 but not by VRQ397 (up to 10 M ; Fig. 6D) ; the calculated EC 50 (ϳ1 nM) of AVP-promoted BRET was in agreement with the EC 50 of AVP for V2R, as reported from classical cAMP assays (71) and cremasteric relaxation (Fig.  5C ), indicating the suitability of the established doubly transfected stable cell line for monitoring V2R activation using BRET (data not show).
Efficacy of VRQ397 on diuresis. Water retention effects of vasopressin are largely dependent upon redistribution of aquaporin-2 on renal epithelial apical cell surface (16) . PGI 2 has recently been suggested to also partake in this process (10) . Since vasopressin-dependent formation of PGI 2 (8, 27, 49, 50, 53) is affected by VRQ397 (Fig. 6B) , we reasoned that VRQ397 would exhibit diuretic properties. VRQ397 increased urine output and water clearance (Fig. 7) without altering creatinine clearance; the latter remained stable (over the same 3-h time span) at 7 Ϯ 0.7 and 6.3 Ϯ 0.7 ml ⅐kg Ϫ1 ⅐min Ϫ1 , respectively, in vehicle-and VRQ397-treated animals, from an average baseline value of 6.7 Ϯ 0.6 ml ⅐kg Ϫ1 ⅐min Ϫ1 .
DISCUSSION
On the basis of site-directed mutagenesis, photo-affinity labeling, and cysteine-scan approaches, a number of crucial regions of GPCR functions have been identified (for a review, see Ref. 40) . Although the second extracellular loop has been highlighted (3, 37) for its roles in both ligand binding and receptor activation, adjacent loops (first and third) also exhibit important properties for various GPCRs (11, 36, 60) , including for vasopressin receptors (29) . On the basis that the second extracellular loop is presumed to fold over the surface of the GPCR requiring destabilization of its interactions with membrane-anchored adjacent loops for ligand binding and activation (14), we designed peptides that reproduce these juxtamembranous regions, and in this process identified an effective hexapeptide, labeled VRQ397 [cravky; directly derived from the original VRQ183 (ALCRAVKY)]. We hereby describe a novel potent, selective, reversible noncompetitive antagonist of V2R, which interferes variably with different signaling responses of V2R; these features distinguish it from competitive antagonists currently available (1) . Consistent with in vitro and ex vivo effects as a V2R antagonist, VRQ397 displayed anticipated in vivo aquaretic efficacy.
VRQ397 arose from regions that are distinct from the V2R natural ligand binding site (orthosteric site) (Fig. 1) , which is located mostly deep within transmembrane regions primarily of transmembrane helix 7 (15, 61) . Because the region from where VRQ397 arises is remote from the orthosteric binding site, derived molecules are noncompetitive antagonists and may affect differently ligand-triggered functions (19, 33, 34) . These features apply to VRQ397. VRQ397 binds specifically to V2R, but does not displace binding of its natural ligand vasopressin (Fig. 5, A-C) , although it modulates vasopressin binding kinetics (Fig. 5D) . The noncompetitive nature of VRQ397 is further substantiated by the inability of high concentrations of DDAVP to surmount antagonistic effects of VRQ397 on DDAVP-induced vasorelaxation (Fig. 5C) ; in contrast, orthosteric antagonism by definition can be overcome by increasing concentrations of the natural ligand (51) .
Consistent with the selectivity of VRQ397 to bind V2R-expressing cells but not to V2R-devoid congener cells, VRQ397 did not bind V1a and oxytocin receptors (Fig. 3C ) and did not affect smooth muscle contraction to stimulation of V1a and oxytocin receptor (Fig. 4) , both of which exhibit different amino acid sequences of the corresponding third juxta-membranous region (respectively, CRVVKH and CRLVKY). This specificity of VRQ397 is further corroborated by its inability to inhibit DDAVP-unrelated endothelium-dependent cremasteric vasorelaxation (to substance P and bradykinin, Fig. 4 , C and D) as well as to downstream mediators of DDAVP-induced vasorelaxation, namely PGI 2 (using the more stable carbacyclin; Fig. 4E) .
It has repeatedly been demonstrated that the ability of a compound to modulate a given signaling pathway cannot be directly extrapolated to another signaling pathway triggered by the same receptor (21, 32, 43) . This infers that such molecules can affect some, but not all, functions evoked by a receptor. These properties referred to as pharmacological permissiveness or functional selectivity apply to VRQ397. We initially utilized a (complex) multi-signal-dependent physiological functional assay to determine efficacy of peptides designed to avoid overseeing antagonistic properties based on single in vitro signaling responses. VRQ397 inhibited V2R-dependent vasorelaxation (induced by DDAVP; Fig. 2, A and B) and downstream signal, notably PGI 2 generation (Fig. 6, A and B) . On the other hand, other signals induced by DDAVP, specifically cAMP generation and ␤-arrestin recruitment, which were fully inhibited by the orthosteric (competitive) antagonist SR121463, were unaffected by VRQ397 (Fig. 6, C and D) . This functional selectivity is likely made possible as a ligand binds the receptor in such a manner as to stabilize its conformation to activate or conversely avoid specific effector systems, characteristic of an allosteric modulator (21, 31, 72) . Hence, by restricting signaling modalities, such ligands may confer greater selectivity and possibly reduce side effects (32), compared with orthosteric antagonists, which disable all functions triggered by the receptor. These features of functional selectivity and allosteric modulation are displayed by VRQ397 and are congruent with those reported for other compounds acting on distinct GPCRs (46, 65) .
Perspectives and Significance
Drug discovery efforts have identified a myriad of orthosteric ligand-based drugs, which by definition interact with the natural ligand binding site. However, difficulties encountered with orthosteric ligands relate to interference of some desirable actions. Allosteric ligands on the other hand have the potential to provide "texture" to the signaling efficacy of the receptor (32) , and thus can preserve desirable actions evoked by receptor stimulation. We hereby exploited these potential advantages by generating the first potent allosteric noncompetitive antagonist of V2R, which derives from the third juxtamembranous region of the receptor, at a site remote from the orthosteric binding site (15, 61) . VRQ397 affects certain DDAVPinduced signaling modalities but not others (Fig. 6) ; this functional selectivity is consistent with characteristics of a negative allosteric modulator (32, 43) . VRQ397, and alike compounds, thus exposes new and interesting properties, notably pharmacological permissiveness, to counter undesired exaggerated effects of V2R stimulation. On the basis of pharmacological characteristics of VRQ397, specifically allosteric noncompetitive antagonist exhibiting pharmacological permissiveness, which are analogous to those we recently described for an antagonist of IL-1 receptor, labeled 101. 10 (44, 48, 62) , we propose the following term for compounds sharing these properties, namely "allosteramer."
